SUDIPTO MUKHERJEE MD
Prescription History 1861692527
Internal Medicine in Royal Oak, MI

NPI Status: Active since July 20, 2007

Contact Information

3601 W 13 MILE RD
ROYAL OAK, MI
ZIP 48073
Phone: (248) 551-0424
Fax: (248) 551-5426

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SUDIPTO MUKHERJEE MD, an active Internal Medicine specialist practicing in Royal Oak, MI. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 192 documented patient claims. Among these therapy options, the most frequently utilized medication is Bosulif, which accounts for 37 claims alone.

Medication Index


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 39.0
Days Supply 1,170
MI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills38.3
Peer Average Days Supply1,033
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $363.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.53

State Avg Cost Per Claim

$27.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Bosulif

Generic Formulation: BosutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 37.0
Days Supply 1,110
MI State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.6
Peer Average Days Supply707
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.9% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $557,687.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,072.64

State Avg Cost Per Claim

$12,852.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Bosutinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Cotellic

Generic Formulation: Cobimetinib FumarateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 322
MI State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$8,546.88

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Cobimetinib is used to treat a type of skin cancer (melanoma). It is also used to treat a certain group of blood cancers (histiocytic neoplasms). It works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 30.0
Days Supply 898
MI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply756
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $150,899.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,029.97

State Avg Cost Per Claim

$2,841.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
MI State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply935
Conservative Utilization

This provider writes prescriptions for this formulation 41.9% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $314,212.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,456.27

State Avg Cost Per Claim

$15,051.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Methotrexate

Generic Formulation: Methotrexate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 24.3
Days Supply 633
MI State Average Benchmarks
Peer Average Claims89.0
Peer Average 30-Day Fills184.0
Peer Average Days Supply5,411
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.3% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,128.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.61

State Avg Cost Per Claim

$42.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Therapeutic Applications

Methotrexate is used to treat certain types of cancer (such as acute lymphoblastic leukemia, non-Hodgkin's lymphoma) or to control severe psoriasis or rheumatoid arthritis that has not responded to other treatments. It may also be used to control juvenile rheumatoid arthritis. Methotrexate belongs to a class of drugs known as antimetabolites. It works by slowing or stopping the growth of cancer cells and suppressing the immune system. Early treatment of rheumatoid arthritis with more aggressive therapy such as methotrexate helps to reduce further joint damage and to preserve joint function.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 19.0
Days Supply 570
MI State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills123.8
Peer Average Days Supply3,661
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.7% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $261.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.67

State Avg Cost Per Claim

$17.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Sprycel

Generic Formulation: DasatinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 890
MI State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply597
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.0% higher than the standard regional baseline profile for MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $233,009.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,281.54

State Avg Cost Per Claim

$11,973.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 16.6
Days Supply 476
MI State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.3
Peer Average Days Supply427
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $339,552.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,119.45

State Avg Cost Per Claim

$14,349.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SUDIPTO MUKHERJEE MD provides transparency into local medical care patterns within Royal Oak, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.